Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically “cold” tumors
Read more at globenewswire.comXilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
XILIO THERAPEUTICS INC
NASDAQ:XLO (2/12/2025, 8:00:03 PM)
After market: 1.3501 -0.13 (-8.78%)1.48
+0.82 (+125.27%)
XLO Latest News and Analysis
8 hours ago - ChartmillKeep an eye on the top gainers and losers in Wednesday's session.Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
9 hours ago - ChartmillThese stocks are the most active in today's sessionLet's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.
10 hours ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
12 hours ago - ChartmillTraders are paying attention to the gapping stocks in Wednesday's session.The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
